Loading...
Loading...
Medical imaging (X-ray, CT, MRI), electronic health records, clinical trials, ECG/EEG, pathology
12,305 datasets
684 infection-related pediatric intensive care unit admissions from the PhysioNet Paediatric Intensive Care database were analyzed to develop a risk prediction model. The study by Yuhang Wang, last updated in June 2026, compared LASSO, random forest, XGBoost, and a stacked ensemble to predict major adverse events within 72 hours. The random forest model achieved an AUC of 0.724 in an internal test set.
684 infection-related pediatric ICU admissions from the PhysioNet database were used to develop a risk prediction model for major adverse events within 72 hours. The study compared LASSO, random forest, XGBoost, and a stacked ensemble, with random forest achieving an AUC of 0.724 in an internal test set. The model framework uses features extracted from admission (0–6 hours) and early reassessment (12–36 hours) windows.
684 infection-related pediatric intensive care unit admissions from the PhysioNet Paediatric Intensive Care database form the analytic cohort. The dataset was used to develop and validate a risk prediction model for 72-hour major adverse events, authored by Yuhang Wang and last updated in June 2026. It compares LASSO, random forest, XGBoost, and a stacked ensemble model.
The PhysioNet Paediatric Intensive Care database provided 684 infection-related PICU admissions for this analysis. The dataset was created by Yuhang Wang to develop and validate an early risk prediction model for short-term major adverse events. It was last updated on June 4, 2026.
A partitioned survival model with a 35-year simulation horizon compares the cost-effectiveness of ibrutinib-venetoclax versus ibrutinib-placebo for relapsed or refractory mantle cell lymphoma. The dataset, authored by Jing He and last updated on 2026-05-21, contains results from a cost-effectiveness analysis conducted from healthcare perspectives in China and the United States. Primary outcomes likely include total costs, life-years, quality-adjusted life-years, and incremental cost-effectiveness ratios.
16 parents with type 2 diabetes were interviewed about their perceptions of diabetes risk for their minor children. The study, conducted from June to August 2025 at a hospital in Zhenjiang, identified three core themes including cognitive biases and behavioral dilemmas. Author Jingjing Wang published the qualitative analysis on figshare under a CC-BY-4.0 license.
Yiming Shi's prospective observational study evaluates the Gastrointestinal Dysfunction Score (GIDS) in 486 adult ICU patients, 359 of whom had pre-existing digestive disease. The dataset likely contains daily scores for GIDS, SOFA, and AGI grades during the first ICU week, used to predict 28-day mortality. The study found that adding GIDS to SOFA improved discrimination, with a combined AUC of 0.764.
A dataset from a prospective observational study evaluating the Gastrointestinal Dysfunction Score (GIDS) in 486 adult ICU patients, including 359 with pre-existing digestive disease. The study, authored by Yiming Shi and shared on figshare, compares GIDS and the Sequential Organ Failure Assessment (SOFA) score for predicting 28-day mortality. Results indicate GIDS combined with SOFA achieved an AUC of 0.764 for mortality discrimination.
Yiming Shi's prospective observational study evaluates the Gastrointestinal Dysfunction Score (GIDS) in adult ICU patients. The dataset includes 486 patients, with 359 having pre-existing digestive system disease, and records daily GIDS, SOFA, and AGI scores for the first ICU week. The study found that combining GIDS with SOFA improved discrimination for 28-day mortality, achieving an AUC of 0.764.
A prospective observational study dataset evaluating the Gastrointestinal Dysfunction Score (GIDS) for predicting 28-day mortality in ICU patients with pre-existing digestive system disease. The dataset includes 486 adult ICU patients, with 359 in the GI cohort, and was created by Yiming Shi. It was last updated on May 28, 2026.
A single-center prospective observational study of 486 adult ICU patients, including 359 with pre-existing digestive disease, conducted by Yiming Shi. The dataset, last updated in May 2026, evaluates the Gastrointestinal Dysfunction Score (GIDS) and its combination with the SOFA score for predicting 28-day mortality.
92 adverse event reports for perfluorohexyloctane ophthalmic solution were analyzed from the FDA Adverse Event Reporting System (FAERS) database from Q4 2023 to Q4 2024. The study by Zhengtai Sun, posted in 2026, employed four disproportionality analysis methods to identify potential safety signals. The median time-to-onset for reported adverse events was 2 days.
Zhengtai Sun conducted a retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database from the fourth quarter of 2023 through the fourth quarter of 2024. The study identified 92 adverse event reports associated with perfluorohexyloctane ophthalmic solution for dry eye disease. It employed four disproportionality analysis methods to identify potential safety signals, with a median time-to-onset for adverse events of 2 days.
A pharmacovigilance analysis of adverse events associated with perfluorohexyloctane ophthalmic solution for dry eye disease. The dataset contains 92 adverse event reports from the FDA Adverse Event Reporting System (FAERS) database from the fourth quarter of 2023 through the fourth quarter of 2024. The study was authored by Zhengtai Sun and posted on figshare.
Zhengtai Sun's pharmacovigilance study analyzes 92 adverse event reports for perfluorohexyloctane ophthalmic solution, a treatment for dry eye disease. The analysis uses FDA Adverse Event Reporting System (FAERS) data from Q4 2023 through Q4 2024 and employs four disproportionality methods to identify safety signals. The median time-to-onset for reported adverse events was 2 days.
92 adverse event reports for a novel dry eye disease treatment were analyzed from the FDA Adverse Event Reporting System (FAERS) between Q4 2023 and Q4 2024. Zhengtai Sun authored this pharmacovigilance study, which identified the top reported events and calculated safety signals using four disproportionality analysis methods. The median time-to-onset for reported adverse events was 2 days.
A retrospective pharmacovigilance study using FDA Adverse Event Reporting System (FAERS) data from the fourth quarter of 2023 through the fourth quarter of 2024 identified 92 adverse event reports associated with perfluorohexyloctane ophthalmic solution for dry eye disease. The analysis employed four disproportionality methods to detect safety signals, with a median time-to-onset of 2 days for reported events. The dataset was authored by Zhengtai Sun and shared under a CC-BY-4.0 license.
A retrospective clinical dataset of 300 acute ischemic stroke patients treated with intravenous thrombolysis, used to develop a prognostic model. The dataset includes a development cohort of 200 patients, a temporal validation cohort of 100 patients, and a dynamic substudy cohort of 150 patients with serial biomarker sampling. It was authored by Huiyuan Zhang and last updated in June 2026.
94 health providers from 20 public facilities in Ubungo district were surveyed from April 4 to May 25, 2025, to assess fidelity to TB screening guidelines for diabetes patients. The study, conducted by Edwin Christian Chavala, found an overall provider-level fidelity score of 83.0%, with 78 out of 94 providers reporting high fidelity. Factors like teamwork, self-efficacy, and facility level were significantly associated with implementation consistency.
A cross-sectional study from April 4th to May 25th, 2025, assessed provider-level implementation fidelity for tuberculosis screening among diabetes patients. The dataset includes survey responses from 94 health providers across 20 public health facilities in Ubungo district, Tanzania. It was created by Edwin Christian Chavala and published on figshare under a CC-BY-4.0 license.